Complement Therapeutics at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Complement Therapeutics brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on an AAV gene therapy for dry age-related macular degeneration that blocks complement activity in the eye. It covers target engagement in cell and animal models and a potency assay linking transduction to complement inhibition.
| Organization | ESGCT 2026 Attendance |
|---|---|
Complement Therapeutics Munich, Germany | |
Clinical-stage company treating complement-driven diseases; lead CTx001 is an AAV gene therapy for geographic atrophy. | Poster Wed Oct 28 1:30pm–3:30pm CTx001 an AAV2 Mini-CR1 Gene Therapy for dry AMD in Phase-I/II clinical trials: in-vitro and in-vivo Studies Show Potent Complement Target Engagement and Inhibition on different cellular and animal models Clinical trials and translationVectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm A potency assay linking transduction, Mini-CR1 expression and Complement inhibition to support the bioactivity of CTx001an AAV2 gene therapy for dry AMD gene therapy Chair Thu Oct 29 4:00pm–6:00pm SESSION 9d: Manufacturing Manufacturing, CMC and access |
Instantly find 20 buyers from Complement Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction